BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

308 related articles for article (PubMed ID: 22901620)

  • 1. Effect of alternate-week versus continuous dexamethasone scheduling on the risk of osteonecrosis in paediatric patients with acute lymphoblastic leukaemia: results from the CCG-1961 randomised cohort trial.
    Mattano LA; Devidas M; Nachman JB; Sather HN; Hunger SP; Steinherz PG; Gaynon PS; Seibel NL;
    Lancet Oncol; 2012 Sep; 13(9):906-15. PubMed ID: 22901620
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Treatment reduction for children and young adults with low-risk acute lymphoblastic leukaemia defined by minimal residual disease (UKALL 2003): a randomised controlled trial.
    Vora A; Goulden N; Wade R; Mitchell C; Hancock J; Hough R; Rowntree C; Richards S
    Lancet Oncol; 2013 Mar; 14(3):199-209. PubMed ID: 23395119
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Augmented post-remission therapy for a minimal residual disease-defined high-risk subgroup of children and young people with clinical standard-risk and intermediate-risk acute lymphoblastic leukaemia (UKALL 2003): a randomised controlled trial.
    Vora A; Goulden N; Mitchell C; Hancock J; Hough R; Rowntree C; Moorman AV; Wade R
    Lancet Oncol; 2014 Jul; 15(8):809-18. PubMed ID: 24924991
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pulse therapy with vincristine and dexamethasone for childhood acute lymphoblastic leukaemia (CCCG-ALL-2015): an open-label, multicentre, randomised, phase 3, non-inferiority trial.
    Yang W; Cai J; Shen S; Gao J; Yu J; Hu S; Jiang H; Fang Y; Liang C; Ju X; Wu X; Zhai X; Tian X; Wang N; Liu A; Jiang H; Jin R; Sun L; Yang M; Leung AWK; Pan K; Zhang Y; Chen J; Zhu Y; Zhang H; Li C; Yang JJ; Cheng C; Li CK; Tang J; Zhu X; Pui CH
    Lancet Oncol; 2021 Sep; 22(9):1322-1332. PubMed ID: 34329606
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Benefit of intensified treatment for all children with acute lymphoblastic leukaemia: results from MRC UKALL XI and MRC ALL97 randomised trials. UK Medical Research Council's Working Party on Childhood Leukaemia.
    Hann I; Vora A; Richards S; Hill F; Gibson B; Lilleyman J; Kinsey S; Mitchell C; Eden OB
    Leukemia; 2000 Mar; 14(3):356-63. PubMed ID: 10720126
    [TBL] [Abstract][Full Text] [Related]  

  • 6. British OsteoNEcrosis Study (BONES) protocol: a prospective cohort study to examine the natural history of osteonecrosis in older children, teenagers and young adults with acute lymphoblastic leukaemia and lymphoblastic lymphoma.
    Amin N; Kinsey S; Feltbower R; Kraft J; Whitehead E; Velangi M; James B
    BMJ Open; 2019 May; 9(5):e027204. PubMed ID: 31122988
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pulses of vincristine and dexamethasone in addition to intensive chemotherapy for children with intermediate-risk acute lymphoblastic leukaemia: a multicentre randomised trial.
    Conter V; Valsecchi MG; Silvestri D; Campbell M; Dibar E; Magyarosy E; Gadner H; Stary J; Benoit Y; Zimmermann M; Reiter A; Riehm H; Masera G; Schrappe M
    Lancet; 2007 Jan; 369(9556):123-31. PubMed ID: 17223475
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Magnetic resonance imaging detection of avascular necrosis of the bone in children receiving intensive prednisone therapy for acute lymphoblastic leukemia or non-Hodgkin lymphoma.
    Ribeiro RC; Fletcher BD; Kennedy W; Harrison PL; Neel MD; Kaste SC; Sandlund JT; Rubnitz JE; Razzouk BI; Relling MV; Pui CH
    Leukemia; 2001 Jun; 15(6):891-7. PubMed ID: 11417473
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Dexamethasone-based therapy for childhood acute lymphoblastic leukaemia: results of the prospective Dutch Childhood Oncology Group (DCOG) protocol ALL-9 (1997-2004).
    Veerman AJ; Kamps WA; van den Berg H; van den Berg E; Bökkerink JP; Bruin MC; van den Heuvel-Eibrink MM; Korbijn CM; Korthof ET; van der Pal K; Stijnen T; van Weel Sipman MH; van Weerden JF; van Wering ER; van der Does-van den Berg A;
    Lancet Oncol; 2009 Oct; 10(10):957-66. PubMed ID: 19747876
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effect of mitoxantrone on outcome of children with first relapse of acute lymphoblastic leukaemia (ALL R3): an open-label randomised trial.
    Parker C; Waters R; Leighton C; Hancock J; Sutton R; Moorman AV; Ancliff P; Morgan M; Masurekar A; Goulden N; Green N; Révész T; Darbyshire P; Love S; Saha V
    Lancet; 2010 Dec; 376(9757):2009-17. PubMed ID: 21131038
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Osteonecrosis as a complication of treating acute lymphoblastic leukemia in children: a report from the Children's Cancer Group.
    Mattano LA; Sather HN; Trigg ME; Nachman JB
    J Clin Oncol; 2000 Sep; 18(18):3262-72. PubMed ID: 10986059
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Value of high-dose cytarabine during interval therapy of a Berlin-Frankfurt-Munster-based protocol in increased-risk children with acute lymphoblastic leukemia and lymphoblastic lymphoma: results of the European Organization for Research and Treatment of Cancer 58881 randomized phase III trial.
    Millot F; Suciu S; Philippe N; Benoit Y; Mazingue F; Uyttebroeck A; Lutz P; Mechinaud F; Robert A; Boutard P; Marguerite G; Ferster A; Plouvier E; Rialland X; Behard C; Plantaz D; Dresse MF; Philippet P; Norton L; Thyss A; Dastugue N; Waterkeyn C; Vilmer E; Otten J;
    J Clin Oncol; 2001 Apr; 19(7):1935-42. PubMed ID: 11283125
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A randomized trial of induction therapy (daunorubicin, vincristine, prednisone versus daunorubicin, vincristine, prednisone, cytarabine and 6-thioguanine) in adult acute lymphoblastic leukemia with long-term follow-up: an Eastern Cooperative Oncology Group Study (E3486).
    Wiernik PH; Cassileth PA; Leong T; Hoagland HC; Bennett JM; Paietta E; Oken MM;
    Leuk Lymphoma; 2003 Sep; 44(9):1515-21. PubMed ID: 14565653
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A randomized phase-III study of the efficacy of granulocyte colony-stimulating factor in children with high-risk acute lymphoblastic leukemia. Berlin-Frankfurt-Münster Study Group.
    Welte K; Reiter A; Mempel K; Pfetsch M; Schwab G; Schrappe M; Riehm H
    Blood; 1996 Apr; 87(8):3143-50. PubMed ID: 8605328
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Augmented therapy improves outcome for pediatric high risk acute lymphocytic leukemia: results of Children's Oncology Group trial P9906.
    Bowman WP; Larsen EL; Devidas M; Linda SB; Blach L; Carroll AJ; Carroll WL; Pullen DJ; Shuster J; Willman CL; Winick N; Camitta BM; Hunger SP; Borowitz MJ
    Pediatr Blood Cancer; 2011 Oct; 57(4):569-77. PubMed ID: 21360654
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Postinduction dexamethasone and individualized dosing of Escherichia Coli L-asparaginase each improve outcome of children and adolescents with newly diagnosed acute lymphoblastic leukemia: results from a randomized study--Dana-Farber Cancer Institute ALL Consortium Protocol 00-01.
    Vrooman LM; Stevenson KE; Supko JG; O'Brien J; Dahlberg SE; Asselin BL; Athale UH; Clavell LA; Kelly KM; Kutok JL; Laverdière C; Lipshultz SE; Michon B; Schorin M; Relling MV; Cohen HJ; Neuberg DS; Sallan SE; Silverman LB
    J Clin Oncol; 2013 Mar; 31(9):1202-10. PubMed ID: 23358966
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Favorable outcome for children and adolescents with T-cell lymphoblastic lymphoma with an intensive ALL-type therapy without local radiotherapy.
    Grenzebach J; Schrappe M; Ludwig WD; Parwaresch R; Zimmermann M; Gadner H; Riehm H; Reiter A;
    Ann Hematol; 2001; 80 Suppl 3():B73-6. PubMed ID: 11757713
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Outcome of acute lymphoblastic leukemia in children with AL90 regimen: impact of response to treatment and sex difference on prognostic factors.
    Ishii E; Eguchi H; Matsuzaki A; Koga H; Yanai F; Kuroda H; Kawakami K; Ayukawa H; Akiyoshi K; Kamizono J; Tamai Y; Kinukawa N; Okamura J
    Med Pediatr Oncol; 2001 Jul; 37(1):10-9. PubMed ID: 11466717
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Avascular necrosis--an antineoplastic-treatment-related toxicity: the experiences of two institutions.
    Sawicka-Zukowska M; Kajdas L; Muszynska-Roslan K; Krawczuk-Rybak M; Sonta-Jakimczyk D; Szczepanski T
    Pediatr Hematol Oncol; 2006 Dec; 23(8):625-9. PubMed ID: 17065138
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Determinants of outcome after intensified therapy of childhood lymphoblastic leukaemia: results from Medical Research Council United Kingdom acute lymphoblastic leukaemia XI protocol.
    Hann I; Vora A; Harrison G; Harrison C; Eden O; Hill F; Gibson B; Richards S;
    Br J Haematol; 2001 Apr; 113(1):103-14. PubMed ID: 11328289
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.